scholarly journals Association of entirely claims-based frailty indices with long-term outcomes in patients with acute myocardial infarction, heart failure, or pneumonia: a nationwide cohort study in Turkey

Author(s):  
Harun Kundi ◽  
Nazim Coskun ◽  
Metin Yesiltepe
2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
M Ruiz Ortiz ◽  
J.J Sanchez Fernandez ◽  
C Ogayar Luque ◽  
E Romo Penas ◽  
M Delgado Ortega ◽  
...  

Abstract Purpose Women and men with stable coronary artery disease (sCAD) have different clinical features and management, but 1-year prognosis has been reported to be similar in large observational registries. The objective of the present study was to investigate the impact of female sex in the prognosis of the disease in the very long-term. Methods The CICCOR registry (“Chronic ischaemic heart disease in Cordoba”) is a prospective, monocentric, cohort study. From February 1, 2000 to January 31, 2004, all consecutive patients with sCAD attended at two outpatient cardiology clinics in a city of the south of Spain were included in the study and prospectively followed. Differential clinical features of women and men were described and the impact of female sex in long term prognosis was investigated. Results The study sample included 1268 patients, 337 women (27%) and 931 men (73% male). Women were older than men (70±9 versus 65±11 years, p<0.0005), more likely to have hypertension (72% versus 49%, p<0.0005) and diabetes (45% versus 26%), and less likely to be ex-smoker/active smoker (5%/2% versus 49%/9%, p<0.0005). They had more frequently angina in functional class ≥II (22% versus 17%, p=0.04) and atrial fibrillation (8% versus 5%, p=0.04), but had received less frequently coronary revascularization (32% versus 44%, p<0.0005). Prescription of statins (64% versus 68%, p=0.22), antiplatelets (89% versus 93%, p=0.07) and betablockers (67% versus 63%, p=0.28) at first visit was similar than men, but women received more frequently nitrates (78% versus 64%, p<0.0005), angiotensin-conversing enzyme inhibitors or receptor antagonists (56% versus 47%, p=0.004) and diuretics (41% versus 22%, p<0.0005). After up to 17 years of follow-up (median 11 years, IQR 4–15 years, with a total of 12612 patients-years of observation), probabilities of acute myocardial infarction (12% versus 14%, p=0.55) or stroke (14% versus 12%, p=0.40) at median follow up were similar for women and men. However, the risks of hospital admission for heart failure (22% versus 13%, p<0.0005) or cardiovascular death (35% versus 24%, p<0.0005) were significantly higher for women, with a non-significant trend to higher overall mortality (45% versus 39%, p=0.07). After multivariate adjustment, the risks of most events were similar for women and men (Hazard Ratios [95% confidence intervals]: 0.79 [0.55–1.14], p=0.21 for acute myocardial infarction; 0.89 [0.61–1.29], p=0.54 for stroke; 1.13 [0.82–1.57], p=0.46 for admission for heart failure; and 0.92 [0.73–1.16], p=0.48 for cardiovascular death), with a non-significant trend to lower overall mortality (0.83 [0.67–1.02], p=0.08). Conclusion Although women and men with sCAD presents a different clinical profile, and crude rates of hospital admissions for heart failure and cardiovascular death were higher in women, female sex was not an independent prognostic factor in this observational study with up to 17 years of follow-up. Funding Acknowledgement Type of funding source: None


Author(s):  
Hyojung Choi ◽  
Joo Yeon Seo ◽  
Jinho Shin ◽  
Bo Youl Choi ◽  
Yu-Mi Kim

Heart failure (HF) is the major mechanism of mortality in acute myocardial infarction (AMI) during early or intermediate post-AMI period. But heart failure is one of the most common long-term complications of AMI. Applied the retrospective cohort study design with nation representative population data, this study traced the incidence of late-onset heart failure since 1 year after newly developed acute myocardial infarction and assessed its risk factors. Methods and Results: Using the Korea National Health Insurance database, 18,328 newly developed AMI patients aged 40 years or older and first hospitalized in 2010 for 3 days or more, were set up as baseline cohort (12,403). The incidence rate of AMI per 100,000 persons was 79.8 overall, and 49.6 for women and 112.3 for men. A total of 2010 (1073 men, 937 women) were newly developed with HF during 6 years following post AMI. Cumulative incidences of HF per 1000 AMI patients for a year at each time period were 37.4 in initial hospitalization, 32.3 in 1 year after discharge, and 8.9 in 1–6 years. The overall and age-specific incidence rates of HF were higher in women than men. For late-onset HF, female, medical aid, pre-existing hypertension, severity of AMI, duration of hospital stay during index admission, reperfusion treatment, and drug prescription pattern including diuretics, affected the occurrence of late-onset HF. Conclusion: With respect to late-onset HF following AMI, appropriate management including hypertension and medical aid program in addition to quality improvement of AMI treatment are required to reduce the risk of late-onset heart failure.


2019 ◽  
Vol 15 (5) ◽  
pp. 706-712
Author(s):  
D. P. Sichinava ◽  
E. P. Kalaydzhyan ◽  
N. P. Kutishenko ◽  
S. Yu. Martsevich

Aim. To assess the impact of arterial hypertension (AH) on the long-term outcomes in patients after acute myocardial infarction (AMI).Material and methods. 160 patients were included: 106 (66.2%) men and 54 (33.8%) women, average age 74.2±11.2 years, discharged from Moscow hospitals with a diagnosis of AMI (from March 01, 2014 till June 30, 2015) and applied to the city polyclinic №9 in Moscow or its branches for outpatient observation. The information was obtained on the basis of medical documentation of the polyclinic and data of patients’ examination/questioning by phone, conducted every 2 months. The follow-up duration was 1 year, the incidence of cardiovascular complications (CVC) was estimated: death, nonfatal AMI, nonfatal cerebral stroke, new cases of atrial fibrillation (AF), hospitalization for unstable angina, hypertensive crisis, heart failure, unplanned surgical interventions on the heart and blood vessels.Results. AH before the development of reference AMI was observed in 118 (73.4%) patients: 48 women and 70 men; in women, AH was recorded more often than in men: 88.9% and 66.0%, respectively, p<0.05. Patients with AH were older than patients without AH: 63.0 (54.0; 74.0) and 55.5 (49.0; 61.0) years, respectively, p<0.001, among them there were more retirees 76 (64.4%) and patients with disabilities 45 (38.1%), p<0.05. Patients with AH compared with patients without AH were less likely to smoke (18.6% and 38.1%, respectively) and drank alcohol (30.5% and 52.4%, respectively), p<0.05 for both; more likely to visit the outpatient clinic (89.0% and 66.7%, respectively), p<0.05. There were no significant differences between the groups of patients with and without AH in the history of cerebral stroke, AMI, arrhythmia by AF type, diabetes mellitus and obesity, except for angina of tension (18.6% and 2.4%, respectively) and hypercholesterolemia (37.3% and 11.9%, respectively), p<0.05 for both. Despite the fact that patients with AH were significantly more often prescribed antihypertensive, lipid-lowering and antithrombotic drugs before reference AMI, the frequency of their use was low: renin-angiotensin-aldosterone system blockers were prescribed in 70 (59.3%) patients, beta-blockers – in 35 (29.7%), calcium antagonists – in 20 (16.9%), diuretics – in 13(11.0%), antiplatelet agents – in 39 (33.1%), statins – in 9 (7.6%) patients. After one year of follow-up, CVC was registered in 33 (28.0%) patients with AH and 9 (21.4%) patients without AH (p=0.41). There was no statistically significant effect of AH on long-term outcomes of AMI, adjusted risk ratio =1.30 [95% confidence interval 0.68- 2.49], p>0.05. The effect of AH on the development of CVC, estimated using the Kaplan-Mayer curve, was not statistically significant (p=0.120).Conclusion. During 1 year of follow-up after AMI in patients with AH the frequency of CVC – death, nonfatal AMI, nonfatal cerebral stroke, new cases of AF, hospitalization for unstable angina, hypertensive crisis, heart failure – did not exceed the overall frequency of CVC in patients without AH.


BMJ ◽  
2013 ◽  
Vol 346 (feb14 3) ◽  
pp. f521-f521 ◽  
Author(s):  
P. K. Lindenauer ◽  
T. Lagu ◽  
M. B. Rothberg ◽  
J. Avrunin ◽  
P. S. Pekow ◽  
...  

Heart ◽  
2021 ◽  
Vol 107 (5) ◽  
pp. 389-395
Author(s):  
Jianhua Wu ◽  
Alistair S Hall ◽  
Chris P Gale

AimsACE inhibition reduces mortality and morbidity in patients with heart failure after acute myocardial infarction (AMI). However, there are limited randomised data about the long-term survival benefits of ACE inhibition in this population.MethodsIn 1993, the Acute Infarction Ramipril Efficacy (AIRE) study randomly allocated patients with AMI and clinical heart failure to ramipril or placebo. The duration of masked trial therapy in the UK cohort (603 patients, mean age=64.7 years, 455 male patients) was 12.4 and 13.4 months for ramipril (n=302) and placebo (n=301), respectively. We estimated life expectancy and extensions of life (difference in median survival times) according to duration of follow-up (range 0–29.6 years).ResultsBy 9 April 2019, death from all causes occurred in 266 (88.4%) patients in placebo arm and 275 (91.1%) patients in ramipril arm. The extension of life between ramipril and placebo groups was 14.5 months (95% CI 13.2 to 15.8). Ramipril increased life expectancy more for patients with than without diabetes (life expectancy difference 32.1 vs 5.0 months), previous AMI (20.1 vs 4.9 months), previous heart failure (19.5 vs 4.9 months), hypertension (16.6 vs 8.3 months), angina (16.2 vs 5.0 months) and age >65 years (11.3 vs 5.7 months). Given potential treatment switching, the true absolute treatment effect could be underestimated by 28%.ConclusionFor patients with clinically defined heart failure following AMI, ramipril results in a sustained survival benefit, and is associated with an extension of life of up to 14.5 months for, on average, 13 months treatment duration.


2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
S.L Xu ◽  
J Luo ◽  
H.Q Li ◽  
Z.Q Li ◽  
B.X Liu ◽  
...  

Abstract Background New-onset atrial fibrillation (NOAF) complicating acute myocardial infarction (AMI) has been associated with poor survival, but the clinical implication of NOAF on subsequent heart failure (HF) is still not well studied. We aimed to investigate the relationship between NOAF following AMI and HF hospitalization. Methods This retrospective cohort study was conducted between February 2014 and March 2018, using data from the New-Onset Atrial Fibrillation Complicating Acute Myocardial Infarction in ShangHai registry, where all participants did not have a documented AF history. Patients with AMI who discharged alive and had complete echocardiography and follow-up data were analyzed. The primary outcome was HF hospitalization, which was defined as a minimum of an overnight hospital stay of a participant who presented with symptoms and signs of HF or received intravenous diuretics. Results A total of 2075 patients were included, of whom 228 developed NOAF during the index AMI hospitalization. During up to 5 years of follow-up (median: 2.7 years), 205 patients (9.9%) experienced HF hospitalization and 220 patients (10.6%) died. The incidence rate of HF hospitalization among patients with NOAF was 18.4% per year compared with 2.8% per year for those with sinus rhythm. After adjustment for confounders, NOAF was significantly associated with HF hospitalization (hazard ratio [HR]: 3.14, 95% confidence interval [CI]: 2.30–4.28; p&lt;0.001). Consistent result was observed after accounting for the competing risk of all-cause death (subdistribution HR: 3.06, 95% CI: 2.18–4.30; p&lt;0.001) or performing a propensity score adjusted multivariable model (HR: 3.28, 95% CI: 2.39–4.50; p&lt;0.001). Furthermore, the risk of HF hospitalization was significantly higher in patients with persistent NOAF (HR: 5.81; 95% CI: 3.59–9.41) compared with that in those with transient NOAF (HR: 2.61; 95% CI: 1.84–3.70; p interaction = 0.008). Conclusion NOAF complicating AMI is strongly associated with an increased long-term risk of heart. Cumulative incidence of outcome Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): 1. National Natural Science Foundation of China, 2. Natural Science Foundation of Shanghai


Sign in / Sign up

Export Citation Format

Share Document